Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2025-11-23 Major Shareholding Noti…
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Becoming a substantial holder - Matt Corp WA PL 2 pages 224.5KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of Initial Substantial Security Holder' and details the substantial shareholding of Matt Corp WA Pty Ltd in Nyrada Inc. It provides specific information about the number of shares and voting power, referencing relevant sections of the Corporations Act 2001 (Cth). There is no financial data, management discussion, or report content. The document is a notification of a change in significant share ownership levels, which fits the definition of a Major Shareholding Notification (MRQ). The document length is 4058 characters, which is consistent with a notice rather than a full report. Therefore, the appropriate classification is MRQ with high confidence.
2025-11-23 English
Application for quotation of securities - NYR 6 pages 18.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement from NYRADA INC. regarding the application for quotation of securities on the ASX. It details the securities issued as a result of options being exercised or convertible securities being converted, including the number of securities, issue date, and other related information. The document is an official application for listing new securities rather than a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues or capital structure changes. The document length is over 6000 characters and contains detailed information about the securities to be quoted, consistent with a capital change announcement rather than a brief notice or regulatory filing.
2025-11-23 English
Cleansing Statement 3 pages 240.0KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Cleansing Statement' and announces the issue of 125,000 CHESS Depositary Interests (CDIs) related to options exercised. It references compliance with sections of the Corporations Act 2001 (Cth) and states that the CDIs were issued without disclosure under Part 6D.2 of the Corporations Act. The document is short (4175 characters) and primarily serves as a regulatory notice about a share issue event rather than a detailed financial report or analysis. It does not contain financial statements or detailed financial data. The content aligns with announcements related to share issues or capital changes. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA).
2025-11-23 English
Nyrada Phase IIa Clinical Trial Update 6 pages 328.0KB
Capital/Financing Update Classification · 90% confidence The document is a detailed update on Nyrada Inc.'s Phase IIa clinical trial for their drug Xolatryp, including trial design, objectives, patient recruitment, and regulatory submissions. It is not a financial report, earnings release, or regulatory filing. It does not contain financial statements or results but rather clinical trial progress and plans. The document is an announcement providing detailed information about the clinical trial status and protocol, which aligns with a Capital/Financing Update (CAP) category as it relates to development progress and potential future capital implications. It is not an Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or report publication announcement. Therefore, the best fit is Capital/Financing Update (CAP).
2025-11-17 English
Application for quotation of securities - NYR 8 pages 24.0KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and contains detailed information about securities issued, transferred, or re-classified due to options being exercised or convertible securities being converted. It includes specifics such as the number of securities, issue dates, issue prices, and the classes of securities involved. The document is an official application to the ASX (Australian Securities Exchange) for the quotation of these securities. This type of filing corresponds to announcements regarding new share issues or capital changes, specifically the application for quotation of newly issued securities. It is not a financial report, earnings release, or management discussion, but rather a capital market announcement related to share issuance and quotation. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (9881 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2025-11-12 English
Cleansing Statement 3 pages 240.0KB
Capital/Financing Update Classification · 95% confidence The document is a Cleansing Statement issued by Nyrada Inc. announcing the issue of CHESS Depositary Interests (CDIs) related to options exercised. It references compliance with sections of the Corporations Act 2001 (Cth) and provides legal disclosures about the issuance of securities without disclosure under Part 6D.2 of the Corporations Act. The document does not contain financial statements, management discussion, or detailed financial results. It is a regulatory announcement about a capital issuance event, specifically the issuance of securities and related legal compliance disclosures. The document length is 4175 characters, which is relatively short and focused on a specific capital/financing update rather than a full report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-11-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.